# US 2008/0171768 A1 · Pharmaceutical Composition Containing An Anti Parasitic Agent And Active Ingredient Selected From Carveol, Thymol, Eugenol, Borneol, Carvacrol, Alpha-Ionone, Or Beta-Ionone

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0171768 A1
- Document ID: US20080171768A1
- Status: Published application
- Kind: A1
- Application number: 11/914,019
- Filed: 2006-05-15
- Published: 2008-07-17
- Earliest claimed: 2005-05-13
- Assignees: Advanced Scientific Developments
- Inventors: Adnane Remmal
- Web page: https://patentgrep.com/patent/US20080171768A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/045: Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K 31/05: Phenols {(cannabinoids A61K31/658)}
- A61P 31/12: Antivirals
- A61P 33/00: Antiparasitic agents
- A61P 33/10: Anthelmintics
- A61P 35/00: Antineoplastic agents
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to a pharmaceutical composition comprising at least one first active therapeutic substance selected among carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, beta-ionone, as well as isomers, derivatives and mixtures thereof, and comprising at least one second active therapeutic substance that is an antiparasitic agent, in particular, an antimalarial agent. The invention is for use in the field of pharmaceutics.

## Claims

### Claim at position 1

1-13. (canceled)

### Claim 14

A pharmaceutical composition comprising:
at least one first therapeutically active substance selected from the group consisting of carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, beta-ionone, and isomers, derivatives or mixtures thereof, and
at least one second therapeutically active substance which is an antiparasitic agent selected from the group consisting of antihelminthics, protozoacides and derivatives or mixtures thereof.

### Claim 15 (depends on 14)

The composition according to claim 14, wherein said second therapeutically active substance is selected from the group consisting of salinomycin, artesunate, mefloquine, chloroquine, and derivatives or mixtures thereof.

### Claim 16 (depends on 14)

The composition according to claim 14, wherein said first therapeutically active substance is selected from the group consisting of thymol, eugenol and carvacrol, and isomers, derivatives or mixtures thereof and said second therapeutically active substance is selected in the group consisting of salinomycin, artesunate, mefloquine, chloroquine, and derivatives or mixtures thereof.

### Claim 17 (depends on 16)

The composition according to claim 16, wherein said first therapeutically active substance is thymol or carvacrol and said second therapeutically active substance is salinomycin.

### Claim 18 (depends on 16)

The composition according to claim 16, wherein said first therapeutically active substance is selected from carvacrol or eugenol and said second therapeutically active substance is selected from the group consisting of salinomycine, artesunate, mefloquine, chloroquine and mixtures thereof.

### Claim 19 (depends on 18)

The composition according to claim 18, wherein said second therapeutically active substance is artesunate.

### Claim 20 (depends on 18)

The composition according to claim 18, wherein said first therapeutically active substance is eugenol and said second therapeutically active substance is selected from the group consisting of artesunate, mefloquine, chloroquine and mixtures thereof.

### Claim 21 (depends on 17)

The composition according to claim 17, wherein said first and second therapeutically active substances are suspended in an aqueous agar solution.

### Claim 22 (depends on 19)

The composition according to claim 19, wherein said first and second therapeutically active substances are suspended in an aqueous agar solution.

### Claim 23 (depends on 20)

The composition according to claim 20, wherein said first and second therapeutically active substances are suspended in an aqueous agar solution.

### Claim 24

A kit comprising:
at least one first container containing a first therapeutically active substance selected from the group consisting of carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, beta-ionone, and isomers, derivatives or mixtures thereof; and
at least one second container containing a second therapeutically active substance which is an antiparasitic agent selected from the group consisting of salinomycin, artesunate, mefloquine, chloroquine, and derivatives or mixtures thereof.

### Claim 25 (depends on 24)

The kit according to claim 24, wherein said first therapeutically active substance is selected from the group consisting of thymol, eugenol and carvacrol, and isomers, derivatives or mixtures thereof.

### Claim 26 (depends on 24)

The kit according to claim 24, wherein said first therapeutically active substance is thymol or carvacrol and said second therapeutically active substance is salinomycin.

### Claim 27 (depends on 24)

The kit according to claim 24, wherein said first therapeutically active substance is selected from carvacrol or eugenol and said second therapeutically active substance is selected from the group consisting of salinomycine, artesunate, mefloquine, chloroquine and mixtures thereof.

### Claim 28 (depends on 27)

The kit according to claim 27, wherein said second therapeutically active substance is artesunate.

### Claim 29 (depends on 24)

The kit according to claim 24, wherein said first therapeutically active substance is eugenol and said second therapeutically active substance is selected from the group consisting of artesunate, mefloquine, chloroquine and mixtures thereof.

### Claim 30

A method for treating an infection caused by a parasite comprising simultaneously or sequentially administering to a patient having a parasitic infection:
at least one first therapeutically active substance selected from the group consisting of carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, beta-ionone and isomers, derivatives or mixtures thereof, and
at least one second therapeutically active substance which is an antiparasitic agent selected from the group consisting of salinomycin, artesunate, mefloquine, chloroquine, and derivatives or mixtures thereof.

### Claim 31 (depends on 30)

The method according to claim 30, wherein said first therapeutically active substance is selected from the group consisting of thymol, eugenol and carvacrol, and isomers, derivatives or mixtures thereof.

### Claim 32 (depends on 30)

The method according to claim 30, wherein said first therapeutically active substance is thymol or carvacrol and said second therapeutically active substance is salinomycin.

### Claim 33 (depends on 30)

The method according to claim 30, wherein said first therapeutically active substance is selected from carvacrol or eugenol and said second therapeutically active substance is selected from the group consisting of salinomycine, artesunate, mefloquine, chloroquine and mixtures thereof.

### Claim 34 (depends on 33)

The method according to claim 33, wherein said second therapeutically active substance is artesunate.

### Claim 35 (depends on 33)

The method according to claim 33, wherein said first therapeutically active substance is eugenol and said second therapeutically active substance is selected from the group consisting of artesunate, mefloquine, chloroquine and mixtures thereof.

### Claim 36 (depends on 30)

The method according to claim 30, wherein said method comprises simultaneously or sequentially administering to a patient having a parasitic infection:
between 10 and 100 mg/kg of body weight/day of said first therapeutically active substance; and
between 20 and 100 mg/kg of body weight/day of said second therapeutically active substance which is an antiparasitic agent.
